QTTB — Q32 Bio Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Q32 Bio Inc

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune func… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$7.09
Market Cap$93.3M
Float9.7M
Shares Outstanding17.0M
P/E (TTM)1.98
Price/Sales (TTM)1.74
vs. Analyst Target+102.2% to analyst PT
Profit Margin61.86%
Operating Margin (TTM)39.84%
Revenue (TTM)$53.7M
Dividend RateNone
Analyst Target Price$14.33 (3 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $2.7M -$129M $2.7M -$120M
2021 $34.0M -$95.8M $24.4M -$86.2M
2022 $6.7M -$42.8M $6.7M -$38.9M
2023 -$6.7M -$53.7M -$6.7M -$47.8M
2024 N/A -$47.7M -$487,000 -$45.3M
2025 $53.7M $29.8M $53.3M $17.3M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$9.5M
Sep 2025 N/A -$7.4M
Dec 2025 $53.7M $57.7M
Mar 2026 N/A -$7.6M

Ownership & Float

Insider Ownership3.9%
Institutional Ownership59.8%
Short Float6.7%

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$6.04Near-term / short-term trend
Weekly40-Week SMA$3.98Medium-term trend
Weekly80-Week SMA$4.02Cyclical trend (business cycle)
Weekly200-Week SMA$16.65Secular trend (multi-year)
Monthly10-Month SMA$3.96Near-term monthly trend
Monthly20-Month SMA$6.56Medium-term monthly trend
Monthly40-Month SMA$14.43Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$1.50 support 6.39x 9 months ago
$27.00 resistance 4.99x 16 months ago
$47.00 resistance 1.42x 17 months ago

Historical Earnings Reactions (33 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.43% 0.00% 48.48% 11.94% -6.73%
1 Day -0.56% 0.00% 45.45% 15.36% -20.26%
1 Week -0.23% 1.32% 51.52% 35.46% -45.98%
2 Weeks 1.29% 1.42% 57.58% 72.85% -48.27%
1 Month 1.16% 2.12% 53.13% 91.28% -87.46%

Next earnings: July 24, 2026 (57 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan2.0%62.5%8
Feb7.1%50.0%8
Mar-6.2%25.0%8
Apr-8.2%22.2%9
May0.4%50.0%8
Jun-0.6%50.0%8
Jul22.3%50.0%8
Aug-2.4%50.0%8
Sep3.5%62.5%8
Oct-5.5%25.0%8
Nov-11.3%37.5%8
Dec-2.7%62.5%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.17% 44.9% 385
Tuesday 0.05% 46.4% 422
Wednesday -0.27% 45.0% 418
Thursday 0.27% 48.8% 412
Friday -0.17% 47.1% 412

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 59.8%

Insider Transactions — Smart Summary

Total insider ownership: 3.9%

Founder-led management: Shelia Violette (Co-founder, Chief Scientific Officer & President of Research)

12-Month Insider Activity Summary

Total Filings8
Net Value-$216,604.721
Net Shares Change-66,008
% of Float-0.7%
C-Suite Filings8
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Morrison Jodie Pope CEO -$141,444.956 3 3 sell
Kalowski Lee CFO and President -$57,066.738 3 3 sell
Violette Shelia M. Chief Scientific Officer -$18,093.026 2 2 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-08-28 – 2025-08-28 3 3 -$31,920.924 3 C-suite
2026-02-27 – 2026-02-27 3 3 -$75,417.566 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-02-27 Morrison Jodie Pope CEO -$44,674.502 Transaction at $4.51, now +57.1%
2026-02-27 Kalowski Lee CFO and President -$18,035.028 Transaction at $4.51, now +57.1%
2026-02-27 Violette Shelia M. Chief Scientific Officer -$12,708.036 Transaction at $4.51, now +57.1%
2025-12-04 Morrison Jodie Pope CEO -$77,870.76 Transaction at $3.46, now +104.9%
2025-12-04 Kalowski Lee CFO and President -$31,395.47 Transaction at $3.46, now +104.9%
2025-08-28 Morrison Jodie Pope CEO -$18,899.694 Transaction at $1.80, now +293.7%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Q32 Bio Inc (QTTB) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for QTTB on Trend Edge →